Compare Organon & Co. Common Stock (OGN) vs Remitly Global Inc (RELY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Remitly Global Inc — how do they compare? Organon & Co. Common Stock trades at $13.77 (market cap $3.61B), while Remitly Global Inc trades at $23.6 (market cap $4.97B). The key difference: Remitly Global Inc is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Remitly Global Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Remitly Global Inc for 53 Days on average.
| OGN | RELY | |
|---|---|---|
Market Cap | $3.61B | $4.97B |
Volume | 1,808,049 | 2,090,383 |
Sector | Health | Technology |
52-Week High | $13.81 | $26.92 |
52-Week Low | $5.70 | $12.20 |
Typical Hold Time | 0 Days | 53 Days |
Enterprise Value | $11.03B | $4.34B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
RELY trades at $23.76, up 0.93% today, with a bullish technical signal from moving averages and strong fundamental momentum. Revenue surged from $654M in 2022 to $1.64B in 2025, with net income turning positive at $67.93M. Recent earnings beats and a partnership with Etsy highlight growth potential, while analyst consensus is strongly bullish with a $30.50 price target.
Outlook is positive given accelerating revenue, expanding margins, and institutional backing, but risks include high valuation multiples and overbought technical indicators. The stock's proximity to its 52-week high suggests near-term resistance, yet long-term growth drivers in digital payments remain compelling for investors seeking exposure to fintech expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
